Chardan Capital Has Lowered Expectations for SAB Biotherapeutics (NASDAQ:SABS) Stock Price
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) had its price objective cut by Chardan Capital from $25.00 to $20.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in […]
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) had its price objective cut by Chardan Capital from $25.00 to $20.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in […]
